2009
Best Doctors
New York Magazine

Peter Gorevic is Professor of Medicine of Chief of the Division of Rheumatology. In ongoing studies, he is examining the pathogenesis of the various forms of amyloid disease, with emphasis on those that are concomitant with the aging process in man, including Alzheimer's disease, and articular amyloid often associated with osteoarthritis. Other studies focus on Dialysis Amyloidosis, a major cause of arthropathy and spondyloarthropathy in patients maintained by long-term dialysis. A variety of agents have been proposed to be generic therapeutics for the treatment of the amyloid diseases, including small peptides corresponding to the subsequences of amyloidogenic proteins, monoclonal antibodies, and compounds that interfere with binding to relevant confactors. A transgenic animal model for dialysis amyloidosis, and an in vitro model for cerebrovascular amyloid are under development, each of which will be used for the development of novel diagnostics and to test therapeutics. Other ongoing studies focus on the autoimmune phenomena and clinical deseases that are extrahepatic manifestations of hepatitis C Virus (HCU), and the potential use of this virus to provoke lymphoproliferative diseases such as non-Hodgkin's lymphoma. In particular, the localization of HCU to cryoprecipitable immune complexes is being examined, as well as the effect of biological such as interferon alpha in inhibitig viral replication and B cell proliferation. These studies are funded by NIH-NIDDK, NIH-NINDS, and the Alzheimer's Association.

Clinical Trials

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
The purpose of this study is to evaluate the safety and effectiveness of Ledipasvir/Sofosbuvir 90mg/400mg daily in subjects with chronic genotype 1 Hepatitis C virus (HCV) infection with symptoms of cryoglobulinemia: joint pain, vasculitis (inflammation of blood vessels), glomeru...

A Phase 3 Multicenter Multinational Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy – FAP) (APOLLO)
The purpose of this study is to collect information about how patients with FAP respond to the study drug Patisiran (ALN-TTR02) over 18 months. In this study the study drug subjects receive either the active investigational drug patisiran (at a dose of 0.3 mg/kg) or placebo (a du...

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP)
The purpose of this study is to determine whether longer treatment with ISIS 420915 (the study drug) is safe and effective in helping people with mild or moderate Familial Amyloid Polyneuropathy (FAP).   This is a multicenter open-label study. Eligible patients who have s...

A Multicenter International Phase 3 Double-Blind Placebo-Controlled Randomized Study to Evaluate the Efficacy Safety and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)
The purpose of this study is to compare the effects over 30 months of the study drug tafamidis meglumine (hereafter called tafamidis) at two different doses (20 mg and 80 mg) with placebo to find out which is better for treating Transthyretin Cardiomyopathy (TTR-CM). Subject...

A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy ofPatisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Complete a Prior Clinical Study with Patisiran
The purpose of this study is to evaluate the long-term safety and efficacy of patisiran in patients with FAP who have completed a prior study with patisiran. This includes studying any potential improvements in patients' disease (FAP) and any side effects that they may have from ...

A Phase 2/3 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy
The drug being researched is called ISIS 420915. ISIS 420915 is an investigational drug. An "investigational drug" is one that is not approved by regulatory authorities such as "US Food and Drug Administration (FDA)". The drug is not for sale in any country. The purpose of this s...

Wilson L, Reichler B, Gorevic P. Cyoglobulinemic and noncryoglobulinemic neuropathy in chronic hepatitis C virus (HCV) infection [abstract]. Mt Sinai J Med. 2000; 68:. 153-3.

Gorevic PD, Galankis DK. Cryoglobulinemia, Cryofibrinogens and Pyroglobulinemia. In: Detrick B , Hamilton RG, Folds JD, editors. Manual of Molecular and Clinical Laboratory Immunology. 7th ASM Press; 2006. pp101-113.

Dember L, Hawkins P, Hazenberg BP C, Gorevic PD. Eprodisate for the Treatment of AA Amyloidosis. New Eng J Med;.